const {
  Document, Packer, Paragraph, TextRun, HeadingLevel, AlignmentType,
  PageNumber, NumberFormat, Header, Footer, Table, TableRow, TableCell,
  WidthType, BorderStyle, PageBreak, SectionType
} = require('docx');
const fs = require('fs');

function heading1(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 400, after: 200 },
  });
}

function heading2(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 300, after: 150 },
  });
}

function heading3(text) {
  return new Paragraph({
    text,
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 200, after: 100 },
  });
}

function para(text, options = {}) {
  return new Paragraph({
    children: [new TextRun({ text, font: 'Times New Roman', size: 24 })],
    spacing: { before: 80, after: 80, line: 360 },
    alignment: AlignmentType.JUSTIFIED,
    ...options,
  });
}

function bold(text) {
  return new TextRun({ text, bold: true, font: 'Times New Roman', size: 24 });
}

function italic(text) {
  return new TextRun({ text, italics: true, font: 'Times New Roman', size: 24 });
}

function run(text) {
  return new TextRun({ text, font: 'Times New Roman', size: 24 });
}

function mixedPara(...runs) {
  return new Paragraph({
    children: runs,
    spacing: { before: 80, after: 80, line: 360 },
    alignment: AlignmentType.JUSTIFIED,
  });
}

function bulletPara(text) {
  return new Paragraph({
    children: [new TextRun({ text, font: 'Times New Roman', size: 24 })],
    bullet: { level: 0 },
    spacing: { before: 60, after: 60 },
    alignment: AlignmentType.JUSTIFIED,
  });
}

function pageBreak() {
  return new Paragraph({ children: [new PageBreak()] });
}

function emptyLine() {
  return new Paragraph({ children: [new TextRun('')], spacing: { before: 60, after: 60 } });
}

// ── TABLE HELPER ─────────────────────────────────────────────────────────────
function makeTable(headers, rows) {
  const borderStyle = { style: BorderStyle.SINGLE, size: 1, color: '000000' };
  const borders = { top: borderStyle, bottom: borderStyle, left: borderStyle, right: borderStyle, insideHorizontal: borderStyle, insideVertical: borderStyle };

  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map(h =>
      new TableCell({
        borders,
        shading: { fill: 'D0D0D0' },
        children: [new Paragraph({
          children: [new TextRun({ text: h, bold: true, font: 'Times New Roman', size: 20 })],
          alignment: AlignmentType.CENTER,
          spacing: { before: 40, after: 40 },
        })],
      })
    ),
  });

  const dataRows = rows.map(row =>
    new TableRow({
      children: row.map(cell =>
        new TableCell({
          borders,
          children: [new Paragraph({
            children: [new TextRun({ text: cell, font: 'Times New Roman', size: 20 })],
            spacing: { before: 40, after: 40 },
          })],
        })
      ),
    })
  );

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
  });
}

// ══════════════════════════════════════════════════════════════════════════════
//  DOCUMENT CONTENT
// ══════════════════════════════════════════════════════════════════════════════

const doc = new Document({
  numbering: {
    config: [
      {
        reference: 'bullet-list',
        levels: [{
          level: 0,
          format: 'bullet',
          text: '•',
          alignment: AlignmentType.LEFT,
          style: { paragraph: { indent: { left: 720, hanging: 360 } } },
        }],
      },
    ],
  },

  sections: [{
    properties: {
      page: {
        margin: { top: 1440, bottom: 1440, left: 1800, right: 1440 },
      },
    },

    headers: {
      default: new Header({
        children: [
          new Paragraph({
            children: [new TextRun({ text: 'Incidence of Follicular Carcinoma Thyroid in Long-Standing Multinodular Goitre', italics: true, font: 'Times New Roman', size: 20 })],
            alignment: AlignmentType.RIGHT,
          }),
        ],
      }),
    },

    footers: {
      default: new Footer({
        children: [
          new Paragraph({
            children: [
              new TextRun({ text: 'Page ', font: 'Times New Roman', size: 20 }),
              new TextRun({ children: [PageNumber.CURRENT], font: 'Times New Roman', size: 20 }),
            ],
            alignment: AlignmentType.CENTER,
          }),
        ],
      }),
    },

    children: [

      // ── TITLE PAGE ──────────────────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: '', break: 3 })],
      }),
      new Paragraph({
        children: [new TextRun({ text: 'INCIDENCE OF FOLLICULAR CARCINOMA THYROID', bold: true, font: 'Times New Roman', size: 36, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 200 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'IN LONG-STANDING MULTINODULAR GOITRE', bold: true, font: 'Times New Roman', size: 36, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 400 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'A THESIS', bold: true, font: 'Times New Roman', size: 28 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 200 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Submitted in Partial Fulfillment of the Requirements for the Award of the', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 100 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Degree of Doctor of Medicine (M.D.) / Master of Surgery (M.S.)', bold: true, font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 400 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Department of General Surgery', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 100 },
      }),
      new Paragraph({
        children: [new TextRun({ text: '[Name of Medical College / University]', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 100 },
      }),
      new Paragraph({
        children: [new TextRun({ text: '[Year of Submission]', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 600 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Candidate: ___________________________', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 120 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Guide / Supervisor: ___________________________', font: 'Times New Roman', size: 24 })],
        alignment: AlignmentType.CENTER,
        spacing: { after: 120 },
      }),
      pageBreak(),

      // ── CERTIFICATE ─────────────────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: 'CERTIFICATE', bold: true, font: 'Times New Roman', size: 32, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 200, after: 400 },
      }),
      para('This is to certify that the thesis entitled "Incidence of Follicular Carcinoma Thyroid in Long-Standing Multinodular Goitre" has been prepared by [Candidate Name], under my guidance and supervision, in partial fulfillment of the requirements for the degree of [Degree].'),
      emptyLine(),
      para('This work has not been submitted for the award of any other degree or diploma in any university or institution.'),
      new Paragraph({ children: [new TextRun({ text: '', break: 6 })] }),
      new Paragraph({
        children: [
          new TextRun({ text: 'Signature of Guide/Supervisor: ______________________', font: 'Times New Roman', size: 24 }),
        ],
        spacing: { before: 200 },
      }),
      pageBreak(),

      // ── DECLARATION ─────────────────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: 'DECLARATION', bold: true, font: 'Times New Roman', size: 32, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 200, after: 400 },
      }),
      para('I hereby declare that the research work presented in this thesis entitled "Incidence of Follicular Carcinoma Thyroid in Long-Standing Multinodular Goitre" is my own work, conducted under the supervision of [Guide Name], Department of General Surgery, [Institution Name].'),
      emptyLine(),
      para('All information in this document has been obtained and presented in accordance with academic rules and ethical conduct. I have fully cited and referenced all material and results that are not original to this work and have obtained their permission where necessary.'),
      pageBreak(),

      // ── ACKNOWLEDGEMENTS ────────────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: 'ACKNOWLEDGEMENTS', bold: true, font: 'Times New Roman', size: 32, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 200, after: 400 },
      }),
      para('I would like to express my sincere gratitude to my guide, [Guide Name], for the continuous support, mentorship, and valuable guidance throughout the course of this study. I am deeply grateful to the Department of General Surgery and the Department of Pathology for their cooperation and use of departmental facilities.'),
      emptyLine(),
      para('My special thanks to the patients who participated in this study, the laboratory staff for their assistance in histopathological processing, and to my family for their unfailing moral support.'),
      pageBreak(),

      // ── TABLE OF CONTENTS ───────────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: 'TABLE OF CONTENTS', bold: true, font: 'Times New Roman', size: 28, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 200, after: 400 },
      }),
      ...[
        ['1.', 'Introduction', '1'],
        ['2.', 'Aims and Objectives', '6'],
        ['3.', 'Review of Literature', '7'],
        ['   3.1', 'The Thyroid Gland — Anatomy and Physiology', '7'],
        ['   3.2', 'Multinodular Goitre (MNG) — Definition and Pathogenesis', '11'],
        ['   3.3', 'Malignant Transformation in MNG', '17'],
        ['   3.4', 'Follicular Carcinoma of the Thyroid — Clinicopathology', '22'],
        ['   3.5', 'Molecular Pathogenesis', '30'],
        ['   3.6', 'Diagnostic Evaluation', '34'],
        ['   3.7', 'Management', '42'],
        ['   3.8', 'Prognosis and Staging', '47'],
        ['4.', 'Materials and Methods', '52'],
        ['5.', 'Observation and Results', '57'],
        ['6.', 'Discussion', '75'],
        ['7.', 'Summary and Conclusions', '88'],
        ['8.', 'Bibliography', '91'],
        ['9.', 'Appendices', '98'],
      ].map(([num, title, page]) =>
        new Paragraph({
          children: [
            new TextRun({ text: `${num}   ${title}`, font: 'Times New Roman', size: 22 }),
            new TextRun({ text: `   .........   ${page}`, font: 'Times New Roman', size: 22 }),
          ],
          spacing: { before: 80, after: 80 },
        })
      ),
      pageBreak(),

      // ── LIST OF ABBREVIATIONS ───────────────────────────────────────────────
      new Paragraph({
        children: [new TextRun({ text: 'LIST OF ABBREVIATIONS', bold: true, font: 'Times New Roman', size: 28, allCaps: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 200, after: 300 },
      }),
      makeTable(
        ['Abbreviation', 'Full Form'],
        [
          ['MNG', 'Multinodular Goitre'],
          ['FTC', 'Follicular Thyroid Carcinoma'],
          ['PTC', 'Papillary Thyroid Carcinoma'],
          ['ATC', 'Anaplastic Thyroid Carcinoma'],
          ['MTC', 'Medullary Thyroid Carcinoma'],
          ['FNAC', 'Fine Needle Aspiration Cytology'],
          ['NIFTP', 'Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features'],
          ['TSH', 'Thyroid Stimulating Hormone'],
          ['T3', 'Triiodothyronine'],
          ['T4', 'Thyroxine'],
          ['US / USG', 'Ultrasonography'],
          ['CECT', 'Contrast-Enhanced Computed Tomography'],
          ['RAI', 'Radioactive Iodine'],
          ['TFT', 'Thyroid Function Test'],
          ['WHO', 'World Health Organization'],
          ['ID', 'Iodine Deficiency'],
          ['PTMC', 'Papillary Thyroid Microcarcinoma'],
          ['ITC', 'Incidental Thyroid Carcinoma'],
          ['LN', 'Lymph Node'],
          ['RLN', 'Recurrent Laryngeal Nerve'],
          ['HPE', 'Histopathological Examination'],
        ]
      ),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 1 — INTRODUCTION
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 1: INTRODUCTION'),
      para('The thyroid gland, nestled in the anterior neck, is one of the most surgically significant endocrine organs. Its disorders range from benign diffuse enlargements to malignant neoplasms with diverse biological behavior. Among the spectrum of thyroid pathology, multinodular goitre (MNG) represents the most prevalent condition encountered in clinical surgical practice worldwide, particularly in iodine-deficient regions.'),
      emptyLine(),
      para('Multinodular goitre is defined as a thyroid gland that has been enlarged by the formation of multiple nodules, the result of a hyperplastic-involutional cycle driven chiefly by fluctuating thyroid stimulating hormone (TSH) stimulation, dietary iodine deficiency, genetic predisposition, and other goitrogens. The prevalence is significantly higher in females and in endemic areas, where the condition may persist for decades — hence the term "long-standing" multinodular goitre. The condition carries a globally reported incidence of thyroid carcinoma ranging from 3% to 31% in series of patients undergoing thyroidectomy for MNG.'),
      emptyLine(),
      para('Thyroid carcinoma is the most common malignancy of the endocrine system. Among its histological subtypes — papillary, follicular, medullary, and anaplastic — follicular thyroid carcinoma (FTC) occupies a unique niche. FTC accounts for approximately 10–15% of all thyroid malignancies in iodine-sufficient regions but assumes proportionally greater significance in iodine-deficient endemic regions, where the papillary-to-follicular ratio shifts dramatically. In regions with dietary iodine deficiency, follicular carcinoma may be the most prevalent subtype, constituting up to 25–40% of all thyroid cancers encountered at surgery.'),
      emptyLine(),
      para('A historically debated question is whether the risk of malignancy — and specifically of follicular carcinoma — is significantly higher in a long-standing multinodular goitre compared to a solitary nodule. Traditional dogma held that the risk in MNG was lower, citing the reassurance of multiple nodules as evidence of benign hyperplasia. Contemporary evidence has challenged this view. A 2022 systematic review and meta-analysis (Rehman et al., Thyroid Research) encompassing 50,321 patients demonstrated that while MNG carried a slightly lower overall odds of malignancy compared to solitary thyroid nodule (OR = 0.76; 95% CI 0.61–0.96), the absolute risk was by no means negligible — papillary carcinoma was the most frequent subtype, followed closely by follicular and medullary carcinomas.'),
      emptyLine(),
      para('Crucially, in iodine-deficient populations, the pattern is reversed: follicular carcinoma predominates. A retrospective study from Khartoum Teaching Hospital, Sudan (2024), examining long-standing goiters found a 32.5% overall malignancy rate, with follicular carcinoma constituting the most common histopathological subtype (42.6% of malignancies) — a finding sharply at variance with the global predominance of papillary carcinoma. A significant association was observed between female gender, disease duration, and the follicular subtype. The clinical implication is profound: in endemic iodine-deficient settings where MNG is almost universal, vigilance for follicular carcinoma must be maintained in every patient undergoing thyroidectomy.'),
      emptyLine(),
      para('The diagnosis of follicular carcinoma presents a unique pathological challenge. Unlike papillary carcinoma, it cannot be identified by cytomorphology alone on fine-needle aspiration cytology (FNAC). The definitive diagnosis rests on histopathological evidence of capsular and/or vascular invasion — features that are only assessable on formal paraffin sections of the resected specimen. This means that a benign FNAC result in a nodule within an MNG does not reliably exclude follicular carcinoma, and an increasing number of so-called "incidental" follicular carcinomas are being detected post-thyroidectomy.'),
      emptyLine(),
      para('Molecularly, follicular carcinomas are characterised by RAS point mutations (present in 40–50% of cases) and the PAX8-PPARG translocation (present in 25–35%), which distinguish them from papillary carcinomas harbouring BRAF mutations and RET rearrangements. These molecular markers, now moving into routine clinical use, offer the promise of pre-operative cytological stratification even in indeterminate nodules.'),
      emptyLine(),
      para('The present study was undertaken at [Institution Name] to determine the incidence of follicular carcinoma in patients presenting with long-standing multinodular goitre and undergoing thyroidectomy. We sought to characterise the clinicopathological profile of such patients, compare findings with regional and global literature, and evaluate the role of pre-operative investigations in predicting malignancy. The results carry direct implications for the surgical management of MNG in our population and for patient counselling.'),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 2 — AIMS AND OBJECTIVES
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 2: AIMS AND OBJECTIVES'),
      heading2('Primary Aim'),
      para('To determine the incidence of follicular carcinoma of the thyroid in patients with long-standing multinodular goitre undergoing thyroidectomy at [Institution Name].'),
      emptyLine(),
      heading2('Secondary Objectives'),
      bulletPara('To determine the overall incidence of malignancy (all histological types) in long-standing MNG.'),
      bulletPara('To compare the relative frequency of follicular carcinoma with other thyroid malignancies (papillary, medullary, anaplastic) in the same cohort.'),
      bulletPara('To study the clinico-demographic profile (age, sex, duration of goitre, thyroid functional status) of patients with follicular carcinoma arising in MNG.'),
      bulletPara('To evaluate the correlation between pre-operative investigations (FNAC, ultrasonography, radionuclide scan, thyroid function tests) and the final histopathological diagnosis.'),
      bulletPara('To study the gross and microscopic pathological characteristics of follicular carcinoma (minimally invasive vs. widely invasive), including pattern of capsular and vascular invasion.'),
      bulletPara('To assess the utility of the Bethesda System for Reporting Thyroid Cytopathology in categorising aspirates from nodules subsequently confirmed as follicular carcinoma.'),
      bulletPara('To compare the malignancy rate in long-standing MNG (> 5 years) versus MNG of shorter duration.'),
      bulletPara('To identify clinical red flags (rapid enlargement, voice change, dysphagia, fixity, cervical lymphadenopathy) associated with follicular carcinoma in MNG.'),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 3 — REVIEW OF LITERATURE
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 3: REVIEW OF LITERATURE'),

      heading2('3.1  The Thyroid Gland: Anatomy and Physiology'),

      heading3('3.1.1  Surgical Anatomy'),
      para('The thyroid gland is a bilobed, butterfly-shaped endocrine organ situated in the anterior neck, draped around the second to fourth tracheal rings. Each lobe measures approximately 4–6 cm in length, 1.5–2 cm in width, and 2–3 cm in depth, with a combined weight of 25–30 g in the adult. The two lobes are connected across the midline by the isthmus, which overlies the second and third tracheal rings. A pyramidal lobe, remnant of the thyroglossal duct, ascends from the isthmus in approximately 50% of individuals.'),
      emptyLine(),
      para('The gland is enclosed within a true capsule of condensed connective tissue, from which fibrous septa penetrate the parenchyma, incompletely dividing it into lobules. Outside this true capsule lies a false (surgical) capsule formed by the pretracheal fascia, between which run the major vessels and the parathyroid glands.'),
      emptyLine(),
      para('Arterial supply is derived from the superior thyroid artery (first branch of the external carotid) and the inferior thyroid artery (from the thyrocervical trunk). The thyroid ima artery, present in approximately 3% of individuals, ascends directly from the brachiocephalic trunk. Venous drainage is through the superior and middle thyroid veins (into the internal jugular) and the inferior thyroid veins (into the brachiocephalic veins). The lymphatics drain sequentially into pre-laryngeal, pre-tracheal, and para-tracheal nodes, then to deep cervical and ultimately mediastinal nodes — pathways of direct surgical relevance to the staging of thyroid carcinoma.'),
      emptyLine(),
      para('The recurrent laryngeal nerve (RLN) — a branch of the vagus nerve — ascends in the tracheo-oesophageal groove on each side and enters the larynx at the inferior border of the cricothyroid muscle. Its intimate proximity to the inferior thyroid artery and the posterior thyroid capsule makes it the most important structure at risk during thyroid surgery. The external branch of the superior laryngeal nerve innervates the cricothyroid muscle and is vulnerable during ligation of the superior pedicle. The parathyroid glands, usually four in number, lie in predictable but variable positions in relation to the posterior thyroid capsule.'),

      heading3('3.1.2  Histology and Physiology'),
      para('The functional unit of the thyroid is the follicle, a spherical structure lined by a single layer of follicular epithelial cells (thyrocytes) surrounding a lumen filled with colloid — chiefly thyroglobulin. Follicular cell height varies with TSH stimulation: cuboidal in the resting state, columnar during active secretion. Interspersed among the follicles are parafollicular C cells (neuroendocrine origin), which secrete calcitonin.'),
      emptyLine(),
      para('Thyroid hormone synthesis proceeds through a series of steps: iodide trapping (via the sodium-iodide symporter, NIS, on the basolateral membrane), iodide oxidation and organification by thyroid peroxidase (TPO) in the presence of H₂O₂, coupling of iodotyrosines (MIT and DIT) to form T₃ and T₄ within thyroglobulin, endocytosis of colloid, and proteolysis to release free T₃ and T₄ into the circulation. This entire process is under negative feedback control by pituitary TSH, which itself is regulated by hypothalamic TRH and circulating thyroid hormone levels. Iodine deficiency chronically elevates TSH, driving follicular cell hyperplasia — the fundamental initiating event in goitrogenesis.'),

      heading2('3.2  Multinodular Goitre (MNG): Definition, Epidemiology, and Pathogenesis'),

      heading3('3.2.1  Definition and Classification'),
      para('Goitre is defined as any pathological enlargement of the thyroid gland beyond its normal weight (> 30–35 g in adults). Multinodular goitre (MNG) specifically describes a thyroid gland that has undergone nodular transformation due to repeated cycles of follicular hyperplasia and subsequent involution, producing heterogeneous architectural changes including multiple discrete nodules, cysts, areas of haemorrhage, calcification, and fibrosis. The terms "simple", "non-toxic", "euthyroid", and "colloid" are used interchangeably in older literature to describe MNG without functional abnormality.'),
      emptyLine(),
      para('The WHO classifies goitre by palpation grade:'),
      bulletPara('Grade 0: No palpable or visible goitre.'),
      bulletPara('Grade 1: Palpable goitre not visible with neck in normal position.'),
      bulletPara('Grade 2: Clearly visible goitre.'),

      heading3('3.2.2  Epidemiology'),
      para('Goitre is among the most common endocrine disorders globally. The WHO estimates that over 800 million people worldwide live in iodine-deficient areas, with endemic goitre affecting a significant proportion. In India, Pakistan, Nepal, and parts of sub-Saharan Africa and South America — areas with historical iodine deficiency — MNG prevalence in surgical series can be as high as 50–60% of all thyroid operations. Female predominance is universal (F:M ratio approximately 4–8:1), attributable to both oestrogen-mediated TSH sensitisation and the physiological iodine demands of pregnancy and lactation.'),
      emptyLine(),
      para('A systematic review and meta-analysis (Rehman et al., 2022, Thyroid Research) encompassing 50,321 patients found that multinodular goitre patients constituted 55.37% of thyroid surgery cohorts, compared to 44.2% with solitary thyroid nodules. The overall malignancy rate in MNG was lower than in solitary nodules (OR = 0.76; 95% CI 0.61–0.96), although the absolute numbers remain clinically substantial.'),

      heading3('3.2.3  Pathogenesis of MNG'),
      para('The pathogenesis of MNG is multifactorial and best understood as a consequence of the sustained mitogenic stimulation of follicular cells, leading to polyclonal and, over time, monoclonal expansion of hyperplastic foci.'),
      emptyLine(),
      mixedPara(bold('Iodine deficiency: '), run('Dietary iodine deficiency is the most important goitrogen worldwide. Iodine deficiency decreases thyroid hormone synthesis, removing negative feedback on the pituitary, and elevating TSH. Chronic TSH stimulation drives follicular cell hypertrophy and hyperplasia. Animal models demonstrate that TSH-driven hyperplasia precedes nodule formation, and that prolonged stimulation induces autonomous, TSH-independent nodular growth — a model directly applicable to long-standing MNG. (Robbins Basic Pathology, 2023)')),
      emptyLine(),
      mixedPara(bold('Goitrogens: '), run('Naturally occurring goitrogens in cassava (thiocyanates), millet, groundnuts, and cruciferous vegetables inhibit iodine uptake or organification. These dietary factors are of particular relevance in endemic regions where both iodine deficiency and high consumption of goitrogenic foods co-exist.')),
      emptyLine(),
      mixedPara(bold('Genetic factors: '), run('Familial aggregation of MNG is well recognised. Mutations in thyroglobulin, TPO, pendrin, and the NIS gene have been documented. Multigenetic susceptibility loci for goitre have been identified on chromosomes 14q and Xp. Molecular studies show that individual nodules within an MNG may be clonally distinct, implying independent acquisition of growth-promoting somatic mutations.')),
      emptyLine(),
      mixedPara(bold('TSH-receptor mutations: '), run('Somatic activating mutations in the TSH receptor gene produce autonomous hyperfunctioning nodules. These are the molecular basis of toxic MNG and are particularly relevant when considering the protective hypothesis (TSH suppression reducing malignancy risk in toxic MNG).')),
      emptyLine(),
      mixedPara(bold('Growth factors and cytokines: '), run('Insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) act as co-mitogens alongside TSH, promoting follicular proliferation and angiogenesis within nodules.')),
      emptyLine(),
      para('The histopathological spectrum within a single MNG is wide: normofollicular, macrofollicular (colloid-distended), microfollicular, Hürthle cell change (oncocytic metaplasia), haemorrhagic cysts, dystrophic calcification, and dense fibrosis may all co-exist. This architectural diversity is of diagnostic importance because it can mimic, or conceal, malignant foci.'),

      heading3('3.2.4  Clinical Features of MNG'),
      para('Patients with MNG typically present with a gradually enlarging neck swelling, often of years to decades duration. Most are euthyroid. Symptoms are predominantly mechanical: pressure on the trachea produces dyspnoea, stridor, and a sensation of tightness; oesophageal compression causes dysphagia; venous obstruction produces the Pemberton sign (facial plethora on raising the arms). Retrosternal extension can cause superior vena caval syndrome, tracheal deviation, and is demonstrable on chest radiograph as a superior mediastinal mass.'),
      emptyLine(),
      para('Sudden increase in the size of a nodule within an MNG — often causing acute pain — is characteristic of haemorrhage into a cyst and must be distinguished from malignant transformation. Features raising the clinical suspicion of malignancy in an MNG include: rapid, progressive enlargement without haemorrhage; fixity to adjacent structures; hard or stony consistency of a nodule; hoarseness (RLN involvement); dysphagia (oesophageal infiltration); and cervical lymphadenopathy. However, these "red flag" features are often absent in follicular carcinoma, which — unlike papillary carcinoma — spreads haematogenously and may present with distant metastases to lung, bone, or liver as the first clinical manifestation.'),

      heading2('3.3  Malignant Transformation in MNG'),

      heading3('3.3.1  Incidence — Historical and Contemporary'),
      para('Early surgical series from the mid-20th century suggested that the risk of malignancy in MNG was low — approximately 2–5% — and substantially lower than in solitary thyroid nodules (10–15%). This view justified conservative management of MNG without aggressive pre-operative investigation.'),
      emptyLine(),
      para('Contemporary literature, however, has revised these estimates considerably upwards:'),
      emptyLine(),
      makeTable(
        ['Study (Year)', 'n', 'Population', 'Overall Malignancy (%)', 'FTC (%)'],
        [
          ['Karalus et al. (2018) N Z Med J', '602', 'New Zealand (mixed)', '16%', 'Not separately reported'],
          ['Chen & Chen (2022) J Chin Med Assoc', '151', 'Taiwan (euthyroid MNG)', '31.1%', '< 2% (PTC predominant)'],
          ['Rehman et al. (2022) Thyroid Res [meta-analysis]', '50,321', 'Global', 'OR 0.76 vs STN', 'FTC 2nd most common'],
          ['Varadharajan & Choudhury (2020) Clin Otolaryngol [systematic review]', 'Multiple series', 'Toxic MNG', '12% (mean)', 'FTC 0.8% (range 0–4.4%)'],
          ['Khartoum Study (2024) PMC12303615', '166', 'Endemic iodine-deficient region', '32.5%', '42.6% of malignancies'],
          ['PMC10335314 (2023)', '1,000', 'Middle East / North Africa', '33.7%', 'FTC as 2nd subtype'],
        ]
      ),
      emptyLine(),
      para('The strikingly higher proportion of follicular carcinoma in endemic iodine-deficient populations (up to 42.6% of malignancies, vs. < 10% in iodine-sufficient areas) represents the most clinically important geographic variation. This correlates with the pathophysiological link between chronic TSH stimulation and follicular-cell neoplasia — a link supported by experimental animal data and epidemiological iodine-substitution studies.'),

      heading3('3.3.2  Risk Factors for Malignancy in MNG'),
      bulletPara('Duration of goitre: Studies from iodine-deficient regions show that longer disease duration is associated with higher malignancy rates, particularly for follicular carcinoma. In the Khartoum study, follicular carcinoma was more prevalent in patients with disease duration < 20 years, suggesting early malignant transformation before the fully involuted end-stage goitre develops.'),
      bulletPara('Female sex: Consistent across all series.'),
      bulletPara('Age at presentation: Younger patients with ITC (incidental thyroid carcinoma) in MNG were a consistent finding (Chen & Chen, 2022; mean age 52.8 vs. 57.2 years for benign MNG, p < 0.05).'),
      bulletPara('Iodine-deficient region of residence.'),
      bulletPara('Family history of thyroid cancer or MEN syndromes.'),
      bulletPara('Previous neck irradiation.'),
      bulletPara('Pre-operatively identified suspicious nodule on ultrasonography (TI-RADS ≥ 4).'),
      bulletPara('Bethesda III–VI cytology on FNAC of a dominant nodule.'),

      heading3('3.3.3  Role of Long-Standing Nature of MNG'),
      para('The concept of "long-standing" MNG implies a chronic, progressive course — typically defined as goitre present for more than 5–10 years. The significance of duration lies in the accumulation of successive somatic mutations in hyperplastic follicular cells. Each cycle of TSH-stimulated proliferation and subsequent involution generates a small but non-zero probability of a mutation in a growth-regulating gene. Over decades, a subset of cells may acquire a constellation of mutations sufficient for neoplastic transformation.'),
      emptyLine(),
      para('The sequential accumulation of RAS mutations is particularly relevant here. RAS mutations are found in benign follicular adenomas (20–40%), follicular carcinomas (40–50%), and even in MNG nodules (10–20%), suggesting a stepwise adenoma-carcinoma sequence: normal follicular cell → hyperplastic nodule → follicular adenoma → minimally invasive FTC → widely invasive FTC. Each step requires additional molecular hits, and the longer the duration of the goitre, the more generations of cells have undergone TSH-driven proliferation and accumulated such mutations.'),

      heading2('3.4  Follicular Carcinoma of the Thyroid: Clinicopathology'),

      heading3('3.4.1  Definition and Classification'),
      para('Follicular thyroid carcinoma (FTC) is defined as a malignant epithelial tumour showing follicular cell differentiation and lacking the diagnostic nuclear features of papillary thyroid carcinoma. The WHO Classification of Tumours (5th Edition, 2022) places FTC within the category of malignant follicular cell-derived neoplasms, alongside papillary carcinoma, oncocytic carcinoma, poorly differentiated carcinoma, and anaplastic carcinoma.'),
      emptyLine(),
      para('FTC is subclassified by the degree of invasiveness:'),
      bulletPara('Minimally invasive FTC: Encapsulated tumour with only microscopic capsular invasion (without vascular invasion, or with < 4 foci of vascular invasion). Carries an excellent prognosis with > 90% 10-year disease-specific survival.'),
      bulletPara('Encapsulated angioinvasive FTC: Capsular invasion ± vascular invasion (4 or more foci). Intermediate prognosis.'),
      bulletPara('Widely invasive FTC: Extensive infiltration of the thyroid parenchyma and/or vessels. Poorer prognosis; up to 50% mortality within 10 years.'),

      heading3('3.4.2  Epidemiology'),
      para('FTC accounts for 10–15% of all thyroid malignancies in iodine-sufficient countries (compared to 75–80% for PTC). In endemic iodine-deficient regions, this proportion rises substantially. The female-to-male ratio is approximately 3:1. Peak incidence is in the fifth to sixth decades of life (40–60 years) — approximately one decade older than for PTC. (Robbins & Kumar Basic Pathology, 2023)'),
      emptyLine(),
      para('After iodine supplementation programmes, the PTC:FTC ratio increases markedly — from approximately 0.2:1 in severely iodine-deficient populations to 4:1 in supplemented populations — providing one of the most compelling epidemiological links between iodine status and thyroid cancer subtype distribution.'),

      heading3('3.4.3  Gross Pathology'),
      para('FTC typically presents as a solitary, encapsulated or partially encapsulated nodule. The cut surface is light-tan to grey, soft to rubbery, and may contain areas of haemorrhage, necrosis, or cystic change. Minimally invasive tumours may be indistinguishable from a follicular adenoma on gross examination — a fact that underscores the absolute dependence on microscopic examination for the diagnosis. Widely invasive tumours show obvious extension through the capsule into adjacent thyroid parenchyma or extrathyroidal soft tissues.'),

      heading3('3.4.4  Microscopic Pathology'),
      para('The cardinal diagnostic criterion for FTC is evidence of capsular and/or vascular invasion. Histopathological evaluation requires systematic and extensive sampling of the tumour-capsule interface.'),
      emptyLine(),
      mixedPara(bold('Capsular invasion: '), run('Defined as tumour cells penetrating fully through the capsule into the peritumoural thyroid parenchyma. Partial capsular penetration (fungating into but not through the capsule) is not sufficient for diagnosis. At least one focus of complete capsular penetration must be demonstrated, ideally with a mushroom-shaped tongue of tumour cells breaching the outer capsular surface.')),
      emptyLine(),
      mixedPara(bold('Vascular invasion: '), run('Defined as tumour emboli within endothelium-lined spaces outside the tumour capsule. Vascular invasion must be distinguished from tumour retraction artefact, and requires the presence of adherent thrombus or endothelial coverage of the tumour cells. The number of foci (< 4 vs. ≥ 4) is prognostically significant.')),
      emptyLine(),
      para('The cellular architecture is typically that of uniform small follicles (microfollicular), trabecular, or solid patterns. Nuclear features of PTC are absent. The diagnosis of follicular carcinoma is established on paraffin histopathology and cannot be reliably made on frozen section or FNAC. This is the fundamental diagnostic limitation that renders pre-operative differentiation from follicular adenoma virtually impossible without molecular testing.'),

      heading3('3.4.5  Clinical Features'),
      para('FTC most frequently manifests as a solitary "cold" nodule on radionuclide scanning — a nodule with reduced radioiodine uptake compared to the surrounding thyroid. Occasional hyperfunctional ("hot") follicular carcinomas are reported but are exceedingly rare. In the context of MNG, the carcinoma may be one of multiple nodules, making identification of the malignant nodule particularly challenging.'),
      emptyLine(),
      para('The hallmark of FTC — and the feature that distinguishes its clinical behaviour from PTC — is its propensity for haematogenous dissemination. Lymph node metastases are uncommon (< 10%). Distant metastases occur in approximately 11–20% of cases at presentation, with the lung (50%), bone (25%), and liver (10%) as the most frequent sites. Bone metastases from FTC can be expansile, lytic, and painful, and may be the presenting feature before the primary tumour is identified.'),

      heading2('3.5  Molecular Pathogenesis'),

      heading3('3.5.1  RAS Mutations'),
      para('Point mutations in the RAS proto-oncogene family (HRAS, KRAS, NRAS) are the most frequent molecular alteration in FTC, occurring in approximately 40–50% of cases. RAS proteins are GTPases that transmit mitogenic signals; activating mutations lock RAS in a constitutively active GTP-bound state, driving continuous cellular proliferation via the MAPK and PI3K-AKT pathways. Importantly, RAS mutations are also found in follicular adenomas (20–40%), supporting the adenoma-carcinoma progression model.'),

      heading3('3.5.2  PAX8-PPARG Translocation'),
      para('The chromosomal translocation t(2;3)(q13;p25), creating a PAX8-PPARG fusion gene, is found in 25–35% of FTCs. PAX8 is a thyroid-specific transcription factor; PPARG (peroxisome proliferator-activated receptor gamma) is a nuclear hormone receptor implicated in terminal differentiation of thyroid epithelial cells. The fusion oncoprotein suppresses PPARG function, impairing differentiation and promoting neoplastic transformation. This rearrangement is also found in a subset of papillary thyroid carcinomas with follicular architecture — specifically the encapsulated follicular variant of PTC — which underscores the molecular continuum between these entities.'),

      heading3('3.5.3  PI3K-AKT-mTOR Pathway'),
      para('Mutations in PTEN (a negative regulator of PI3K) are found in approximately 10–15% of FTCs and in Cowden syndrome (PTEN hamartoma tumour syndrome), where multinodular goitre and follicular carcinoma occur together in a germline setting. PIK3CA mutations and PTEN deletions cooperate with RAS mutations in driving progression from adenoma to carcinoma. The PI3K pathway is an active therapeutic target in thyroid cancer.'),

      heading3('3.5.4  TERT Promoter Mutations'),
      para('Mutations in the TERT (telomerase reverse transcriptase) promoter are present in approximately 17% of FTCs and strongly correlate with disease recurrence, distant metastasis, and disease-specific mortality. When TERT promoter mutations co-occur with RAS mutations, the prognosis is substantially worse than with either mutation alone — the so-called "double-hit" model.'),

      heading2('3.6  Diagnostic Evaluation'),

      heading3('3.6.1  Clinical Assessment'),
      para('A meticulous history and physical examination remain the foundation of thyroid nodule evaluation in MNG. Key points include: duration and rate of growth of the goitre; family history of thyroid cancer; history of neck irradiation; symptoms of compressive pathology (dysphagia, dyspnoea, hoarseness); and systemic features of hyper- or hypothyroidism.'),
      emptyLine(),
      para('On examination: size, consistency, surface texture, mobility, fixity, and regional lymphadenopathy are assessed. A firm or hard dominant nodule within a soft multinodular goitre should raise concern. Tracheal deviation and Pemberton sign are documented. Vocal cord mobility is assessed by laryngoscopy if hoarseness is present.'),

      heading3('3.6.2  Thyroid Function Tests'),
      para('Serum TSH is the single most important initial biochemical investigation. A suppressed TSH suggests functional autonomy (toxic MNG), which historically was thought to confer a degree of protection against malignancy. A systematic review (Varadharajan & Choudhury, 2020, Clin Otolaryngol) found that the mean malignancy rate was 12% in toxic MNG — comparable to or higher than non-toxic MNG — challenging this protective hypothesis. Free T₃ and T₄ are measured if TSH is abnormal.'),

      heading3('3.6.3  Ultrasonography'),
      para('High-resolution neck ultrasound is the primary imaging modality for thyroid nodule characterisation. The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) assigns risk scores from TR1 (benign) to TR5 (high suspicion for malignancy) based on:'),
      bulletPara('Composition (solid vs. cystic vs. spongiform)'),
      bulletPara('Echogenicity (hypoechoic vs. isoechoic vs. hyperechoic)'),
      bulletPara('Shape (wider than tall vs. taller than wide)'),
      bulletPara('Margin (smooth vs. ill-defined vs. lobulated vs. irregular vs. extrathyroidal extension)'),
      bulletPara('Echogenic foci (none vs. comet-tail artefact vs. macrocalcification vs. peripheral rim vs. punctate foci)'),
      emptyLine(),
      para('Features particularly concerning for FTC on ultrasound include a hypoechoic solid mass with a thick irregular capsule, peripheral vascularity, and absence of punctate calcifications (which are more characteristic of PTC). Ultrasound-guided FNAC targets the dominant/suspicious nodule within an MNG.'),

      heading3('3.6.4  Fine-Needle Aspiration Cytology (FNAC)'),
      para('FNAC, interpreted using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), is the cornerstone of pre-operative evaluation. The six Bethesda categories carry the following estimated risks of malignancy:'),
      emptyLine(),
      makeTable(
        ['Bethesda Category', 'Cytological Diagnosis', 'Risk of Malignancy (%)'],
        [
          ['I', 'Non-diagnostic/Unsatisfactory', '5–10'],
          ['II', 'Benign', '0–3'],
          ['III', 'Atypia of Undetermined Significance / FN of UMP', '10–30'],
          ['IV', 'Follicular Neoplasm / Suspicious for FN', '25–40'],
          ['V', 'Suspicious for Malignancy', '50–75'],
          ['VI', 'Malignant', '97–99'],
        ]
      ),
      emptyLine(),
      para('The critical limitation of FNAC in the context of FTC is that follicular cells on cytology cannot be distinguished as adenomatous or carcinomatous — the diagnosis requires capsular/vascular invasion that is simply not assessable on aspirated cells. A Bethesda IV (Follicular Neoplasm) result therefore mandates surgical excision (typically hemithyroidectomy with intraoperative frozen section and conversion to total thyroidectomy if carcinoma confirmed), but a benign Bethesda II result does not exclude follicular carcinoma with certainty.'),
      emptyLine(),
      para('Several studies have demonstrated that incidental FTCs in MNG frequently arise from nodules that were Bethesda II on pre-operative FNAC — emphasising the genuine diagnostic gap. This underscores the argument that patients with long-standing MNG and compressive symptoms should undergo total thyroidectomy rather than conservative or partial resection, allowing complete histopathological examination of all nodules.'),

      heading3('3.6.5  Radionuclide (Nuclear Medicine) Scanning'),
      para('Thyroid scintigraphy using Tc-99m pertechnetate or I-123 classifies nodules as "hot" (hyperfunctional, almost never malignant), "warm" (iso-functional), or "cold" (hypofunctional). In the context of MNG, where multiple nodules are present, scintigraphy is primarily useful to identify toxic MNG (diffusely increased uptake with autonomous nodules) and to exclude hyperfunctioning nodules from FNAC biopsy. Cold nodules in MNG carry a malignancy risk of 10–20%, but most cold nodules are benign.'),

      heading3('3.6.6  Serum Thyroglobulin'),
      para('Serum thyroglobulin (Tg) is not a useful pre-operative marker because it is elevated in any goitre. Its primary utility is as a tumour marker for monitoring recurrence following total thyroidectomy and radioiodine ablation for differentiated thyroid cancer (PTC and FTC). A rising post-operative Tg level is the earliest indicator of recurrent or metastatic disease.'),

      heading3('3.6.7  Molecular Testing'),
      para('Commercial molecular diagnostic panels (e.g., Afirma Gene Sequencer Classifier, ThyroSeq v3) applied to FNAC aspirates from indeterminate nodules (Bethesda III/IV) can improve pre-operative risk stratification. Detection of RAS mutations, PAX8-PPARG translocation, or TERT promoter mutations in an indeterminate aspirate significantly raises the probability of FTC and may guide the decision toward total rather than hemithyroidectomy. These platforms are increasingly available at tertiary centres.'),

      heading3('3.6.8  Computed Tomography (CT) and MRI'),
      para('CECT neck and chest is performed for retrosternal extension, tracheal/oesophageal involvement, mediastinal lymphadenopathy, and pulmonary metastases. MRI is preferred for evaluating vascular invasion and for assessment of locally advanced disease without radiation exposure. Neither CT nor MRI has sufficient resolution to characterise individual nodule histology.'),

      heading2('3.7  Management'),

      heading3('3.7.1  Surgical Treatment'),
      para('Surgery is the definitive treatment for FTC and for MNG with suspected or confirmed malignancy. The extent of surgery has evolved considerably:'),
      emptyLine(),
      mixedPara(bold('Total thyroidectomy: '), run('The standard operation for confirmed or clinically suspected thyroid malignancy, and increasingly the preferred operation for long-standing MNG with compressive symptoms or suspicious cytology. Advantages include: complete removal of the thyroid remnant (eliminating occult contralateral foci), facilitation of post-operative radioiodine ablation, and ability to use serum Tg as a sensitive tumour marker. The principal risks are permanent hypoparathyroidism (1–3%) and recurrent laryngeal nerve injury (< 1% in experienced hands). (Harrison\'s Principles of Internal Medicine, 22nd Ed., 2025)')),
      emptyLine(),
      mixedPara(bold('Hemithyroidectomy + isthmusectomy: '), run('Appropriate initial operation for a solitary indeterminate (Bethesda III/IV) nodule when the contralateral lobe is normal. If final histopathology confirms minimally invasive FTC with low-risk features (< 4 cm, no vascular invasion), completion thyroidectomy may be deferred in selected patients.')),
      emptyLine(),
      mixedPara(bold('Neck dissection: '), run('Central neck dissection (Level VI) is indicated for clinically or radiologically evident central compartment lymph node disease. Lateral neck dissection (Levels II–V) is reserved for biopsy-proven lateral compartment metastases. Prophylactic central neck dissection for FTC is generally not recommended given the low rate of lymph node metastasis.')),

      heading3('3.7.2  Radioiodine (RAI) Ablation'),
      para('Post-operative RAI (I-131) is administered to ablate the thyroid remnant in intermediate- and high-risk differentiated thyroid cancer, facilitating sensitive Tg monitoring and treatment of iodine-avid metastases. The indication for RAI in low-risk minimally invasive FTC (without vascular invasion) is controversial; current ATA guidelines do not recommend routine RAI ablation in this category. For widely invasive FTC and cases with distant metastases, high-dose RAI (100–200 mCi) is the cornerstone of adjuvant therapy.'),

      heading3('3.7.3  TSH Suppression Therapy'),
      para('Levothyroxine is prescribed to suppress TSH to below the normal range in high-risk FTC, reducing the residual TSH-driven growth stimulus on differentiated cancer cells. The degree of suppression (mildly subnormal vs. frankly suppressed) is titrated to the risk category of the disease. Long-term suppression carries risks of osteoporosis and atrial fibrillation and must be balanced against oncological benefit.'),

      heading3('3.7.4  Targeted Therapy'),
      para('For radioiodine-refractory metastatic FTC, multikinase inhibitors (sorafenib, lenvatinib) are approved first-line therapies and have demonstrated significant improvements in progression-free survival in phase III trials. RAS-mutant tumours are under investigation for targeted approaches.'),

      heading2('3.8  Prognosis and Staging'),

      heading3('3.8.1  TNM Staging (AJCC 8th Edition)'),
      para('All differentiated thyroid cancers (DTC) in patients < 55 years of age are classified as Stage I (any T, any N, M0) or Stage II (any T, any N, M1). For patients ≥ 55 years, the T and N categories apply conventionally. This age-based staging reflects the generally excellent prognosis of differentiated thyroid cancer in younger patients, irrespective of local extent.'),
      emptyLine(),
      makeTable(
        ['Risk Category', 'Histological Features', '10-Year Mortality'],
        [
          ['Minimally invasive FTC (no or limited VI)', 'Encapsulated, capsular invasion only, < 4 foci VI', '< 5%'],
          ['Encapsulated angioinvasive FTC', 'Capsular invasion + ≥ 4 foci VI', '15–30%'],
          ['Widely invasive FTC', 'Extensive parenchymal/vascular invasion', '40–50%'],
          ['FTC with distant metastases', 'M1 disease (lung/bone/liver)', '> 50% at 10 years'],
        ]
      ),

      heading3('3.8.2  Prognostic Factors'),
      bulletPara('Age at diagnosis (> 55 years: worse prognosis).'),
      bulletPara('Tumour size (T1: < 2 cm; T4: extrathyroidal extension).'),
      bulletPara('Vascular invasion — number and extent of foci.'),
      bulletPara('Completeness of surgical resection.'),
      bulletPara('RAI avidity.'),
      bulletPara('TERT promoter mutation co-existing with RAS mutation.'),
      bulletPara('Distant metastases at presentation.'),
      emptyLine(),
      para('Overall, the prognosis of FTC is less favourable than PTC but significantly better than poorly differentiated or anaplastic thyroid carcinoma. With complete surgical excision and appropriate adjuvant therapy, minimally invasive FTC carries a near-normal life expectancy.'),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 4 — MATERIALS AND METHODS
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 4: MATERIALS AND METHODS'),

      heading2('4.1  Study Design'),
      para('Prospective observational study with retrospective correlation of pre-operative and operative data with final histopathological findings.'),

      heading2('4.2  Study Setting'),
      para('[Department of General Surgery, in collaboration with Department of Pathology, Institution Name, City]. Duration of study: [Start Date] to [End Date] (approximately 2–3 years).'),

      heading2('4.3  Sample Size Calculation'),
      para('Based on a reported prevalence of follicular carcinoma in long-standing MNG of approximately 5–10%, using a precision of 5% and 95% confidence interval, the minimum required sample size was calculated as:'),
      mixedPara(italic('  n = Z²p(1–p)/d² = (1.96)² × 0.075 × 0.925 / (0.05)² ≈ 107 patients')),
      emptyLine(),
      para('A minimum of 100 patients with confirmed long-standing MNG were targeted for inclusion. All patients meeting inclusion criteria during the study period were enrolled (consecutive sampling).'),

      heading2('4.4  Inclusion Criteria'),
      bulletPara('Age ≥ 15 years.'),
      bulletPara('Clinical and ultrasonographic diagnosis of multinodular goitre.'),
      bulletPara('Duration of goitre ≥ 2 years (confirmed by reliable history, documented medical records, or prior clinical notes).'),
      bulletPara('Patients undergoing hemithyroidectomy, subtotal thyroidectomy, or total thyroidectomy for MNG.'),
      bulletPara('Availability of complete pre-operative data (clinical, biochemical, cytological, and imaging) and final histopathological report.'),
      bulletPara('Written informed consent.'),

      heading2('4.5  Exclusion Criteria'),
      bulletPara('Prior thyroid surgery or radioiodine therapy.'),
      bulletPara('Recurrent goitre.'),
      bulletPara('Autoimmune thyroiditis (Hashimoto\'s or de Quervain\'s) as the primary diagnosis.'),
      bulletPara('Pre-operatively diagnosed differentiated thyroid carcinoma (cytological Bethesda VI) — excluded to focus on incidentally detected malignancies.'),
      bulletPara('Pregnancy.'),
      bulletPara('Incomplete data or follow-up.'),

      heading2('4.6  Pre-Operative Data Collection'),
      para('A structured proforma was developed and validated, capturing:'),
      bulletPara('Demographics: Age, sex, occupation, geographic origin, dietary history (iodine sources, goitrogen consumption).'),
      bulletPara('Clinical: Duration of swelling, rate of growth, compressive symptoms, voice changes, family history, prior neck irradiation.'),
      bulletPara('Examination: Size, consistency, mobility, surface, Pemberton sign, vocal cord mobility on indirect laryngoscopy.'),
      bulletPara('Investigations: TSH, free T4, free T3, anti-TPO antibodies (to exclude Hashimoto\'s thyroiditis), serum calcium, ultrasonography report (TI-RADS category for each nodule), FNAC (Bethesda category), radionuclide scan (where performed), CECT when indicated.'),

      heading2('4.7  Operative Data'),
      para('Type of surgery performed (hemithyroidectomy, subtotal, or total thyroidectomy), extent of neck dissection, intraoperative findings (fixity, vascularity, consistency, lymph node status), and operative complications (haemorrhage, RLN injury, parathyroid devascularisation).'),

      heading2('4.8  Histopathological Examination'),
      para('All excised thyroid specimens were processed by standard formalin fixation, paraffin embedding, and serial haematoxylin and eosin (H&E) staining. The entire capsule of each nodule identified was sectioned at 3 mm intervals for microscopic examination. Histopathological reporting followed WHO 2022 Classification of Endocrine Tumours criteria:'),
      bulletPara('Classification: Follicular adenoma, follicular carcinoma (minimally invasive / encapsulated angioinvasive / widely invasive), papillary carcinoma (including variants), Hürthle cell tumour, medullary carcinoma, anaplastic carcinoma, or benign MNG.'),
      bulletPara('For FTC: Documentation of the number of foci of capsular invasion, presence and number of foci of vascular invasion, and overall invasion category.'),
      bulletPara('Immunohistochemistry (IHC): Performed as indicated (CK19, HBME-1, galectin-3, CD56, calcitonin) to resolve diagnostic uncertainty.'),

      heading2('4.9  Statistical Analysis'),
      bulletPara('Continuous variables: Mean ± standard deviation (SD) for normally distributed data; median with interquartile range (IQR) for skewed data.'),
      bulletPara('Categorical variables: Frequency (n) and percentage (%).'),
      bulletPara('Association between categorical variables: Chi-square test (Fisher exact test for small cell counts).'),
      bulletPara('Association between continuous and categorical variables: Independent t-test or Mann-Whitney U test.'),
      bulletPara('Diagnostic performance of pre-operative tests: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy calculated against the gold standard of HPE.'),
      bulletPara('Statistical significance: p < 0.05 (two-tailed).'),
      bulletPara('Software: SPSS version 27.0 / R version 4.x.'),

      heading2('4.10  Ethical Approval'),
      para('The study was approved by the Institutional Ethics Committee ([Reference Number], [Date]). Informed written consent was obtained from all participants. Patient confidentiality was maintained by anonymisation of data at the time of analysis.'),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 5 — OBSERVATIONS AND RESULTS
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 5: OBSERVATIONS AND RESULTS'),
      para('[Note: The following tables and observations represent a model template. Actual data from the study must be inserted by the candidate.]'),
      emptyLine(),

      heading2('5.1  Demographic Profile'),
      makeTable(
        ['Variable', 'n (%)', 'Mean ± SD'],
        [
          ['Total patients enrolled', '120 (100%)', '—'],
          ['Female', '98 (81.7%)', '—'],
          ['Male', '22 (18.3%)', '—'],
          ['Age (years)', '—', '42.6 ± 11.2'],
          ['Duration of goitre (years)', '—', '9.3 ± 6.7'],
        ]
      ),
      emptyLine(),

      heading2('5.2  Histopathological Findings'),
      makeTable(
        ['Histopathological Diagnosis', 'n', 'Percentage (%)'],
        [
          ['Benign Multinodular Goitre', '85', '70.8'],
          ['Total Malignant', '35', '29.2'],
          ['— Papillary Carcinoma', '17', '14.2'],
          ['— Follicular Carcinoma', '12', '10.0'],
          ['— Follicular variant of PTC', '4', '3.3'],
          ['— Medullary Carcinoma', '1', '0.8'],
          ['— Anaplastic Carcinoma', '1', '0.8'],
        ]
      ),
      emptyLine(),

      heading2('5.3  Incidence of Follicular Carcinoma'),
      para('Of the 120 patients with long-standing MNG undergoing thyroidectomy, follicular carcinoma was identified in 12 patients — an incidence of 10.0% (95% CI: 5.3–16.9%). Among all malignancies, follicular carcinoma accounted for 34.3% of cases. Minimally invasive FTC was the predominant subtype (n = 8, 66.7%), followed by encapsulated angioinvasive FTC (n = 3, 25%) and widely invasive FTC (n = 1, 8.3%).'),
      emptyLine(),

      heading2('5.4  Clinico-Demographic Profile of FTC vs. Benign MNG'),
      makeTable(
        ['Parameter', 'FTC (n=12)', 'Benign MNG (n=85)', 'p-value'],
        [
          ['Mean age (years)', '48.2 ± 9.6', '41.8 ± 11.4', '0.043*'],
          ['Female sex', '10 (83.3%)', '71 (83.5%)', '0.987'],
          ['Duration of goitre (years)', '11.4 ± 7.1', '9.0 ± 6.4', '0.214'],
          ['TSH suppressed (< 0.5 mIU/L)', '2 (16.7%)', '18 (21.2%)', '0.712'],
          ['Dominant cold nodule on USG', '10 (83.3%)', '38 (44.7%)', '0.009**'],
          ['Pre-op FNAC Bethesda IV', '6 (50%)', '12 (14.1%)', '0.003**'],
        ]
      ),
      para('* p < 0.05 (significant); ** p < 0.01 (highly significant)'),
      emptyLine(),

      heading2('5.5  Pre-operative FNAC Correlation with Final HPE'),
      makeTable(
        ['Bethesda Category', 'FTC (n)', 'Benign MNG (n)', 'PTC (n)', 'Total'],
        [
          ['II (Benign)', '5', '60', '3', '68'],
          ['III (AUS/FLUS)', '1', '15', '4', '20'],
          ['IV (Follicular Neoplasm)', '6', '9', '2', '17'],
          ['V (Suspicious)', '0', '1', '6', '7'],
          ['VI (Malignant)', '0', '0', '2', '2'],
          ['Non-diagnostic', '0', '0', '0', '6'],
        ]
      ),
      emptyLine(),
      para('Sensitivity of FNAC for FTC: 50.0%; Specificity: 85.9%; PPV: 35.3%; NPV: 91.9%; Accuracy: 80.0%. Note that 5 of 12 FTC cases (41.7%) had a Bethesda II (Benign) cytological result — confirming the well-established diagnostic limitation of FNAC for follicular carcinoma.'),
      emptyLine(),

      heading2('5.6  Gross and Microscopic Pathology of FTC Cases'),
      makeTable(
        ['Feature', 'Number (n=12)', '%'],
        [
          ['Solitary dominant nodule', '9', '75'],
          ['Incidental in MNG', '3', '25'],
          ['Size > 4 cm', '5', '41.7'],
          ['Capsular invasion only (minimally invasive)', '8', '66.7'],
          ['Vascular invasion present', '4', '33.3'],
          ['Widely invasive pattern', '1', '8.3'],
          ['Hürthle cell (oncocytic) variant', '2', '16.7'],
          ['Lymph node metastasis', '0', '0'],
          ['Distant metastasis at presentation', '1', '8.3'],
        ]
      ),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 6 — DISCUSSION
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 6: DISCUSSION'),

      para('The results of this study demonstrate a 10% incidence of follicular carcinoma of the thyroid among patients with long-standing multinodular goitre undergoing thyroidectomy — a finding with important implications for the surgical management of MNG in our clinical setting.'),
      emptyLine(),
      para('The overall malignancy rate of 29.2% in our series is consistent with contemporary data from iodine-deficient or transitional populations. This is substantially higher than the 5–8% cited in older Western literature and closer to the 16–33% reported in recent studies from New Zealand (Karalus et al., 2018), Taiwan (Chen & Chen, 2022), and Sudan (2024). The convergence of contemporary literature on a higher malignancy risk in MNG reflects improved detection through total thyroidectomy and systematic serial sectioning of specimens, rather than a true increase in biological behaviour.'),
      emptyLine(),
      para('The specific incidence of follicular carcinoma (10%) is of particular interest. In global series from iodine-sufficient countries, FTC constitutes approximately 10–15% of thyroid malignancies. In our study, FTC accounted for 34.3% of all malignancies in MNG — proportionally higher than expected. This is consistent with the iodine-replacement transition status of our population, where historical iodine deficiency has elevated TSH-driven follicular cell proliferation. The PAX8-PPARG and RAS molecular pathways activated under chronic TSH stimulation are directly implicated in this follicular predominance.'),
      emptyLine(),
      para('A pivotal and clinically important finding of this study is the pre-operative diagnostic gap for FTC: 41.7% of confirmed FTCs had a Bethesda II (Benign) cytological result. This confirms the widely acknowledged limitation of FNAC in the diagnosis of follicular malignancy — a limitation that is intrinsic to the methodology, since capsular and vascular invasion (the diagnostic criteria for FTC) cannot be assessed cytologically. The sensitivity of FNAC for FTC in our series was only 50%, consistent with published sensitivities of 40–60% for follicular lesions.'),
      emptyLine(),
      para('This finding argues strongly for a policy of total thyroidectomy rather than subtotal or partial resection for long-standing MNG in endemic populations. The traditional argument for conservative surgery in MNG — that most are benign — underestimates the real risk of occult follicular malignancy, particularly in patients with long-duration goitre, dominant cold nodules, or Bethesda III/IV cytology. Furthermore, total thyroidectomy allows complete histopathological assessment of all nodules, enables post-operative RAI ablation, and facilitates sensitive tumour surveillance using serum Tg. While total thyroidectomy carries a higher complication risk (hypoparathyroidism, RLN injury) than hemithyroidectomy, these risks are acceptably low in experienced hands (< 2% permanent hypoparathyroidism in high-volume centres).'),
      emptyLine(),
      para('The demographic and clinico-pathological correlates identified in this study are consistent with established evidence. The older mean age of patients with FTC (48.2 vs. 41.8 years) aligns with the known peak incidence of FTC in the fifth to sixth decade. The female predominance in both FTC and benign MNG groups reflects the universal sex predilection of thyroid disease. The longer duration of goitre in the FTC group (11.4 vs. 9.0 years, although not reaching statistical significance in this series), is biologically plausible: long-standing TSH stimulation provides more opportunity for accumulation of pro-oncogenic somatic mutations (RAS, TERT, PTEN) in hyperplastic follicular cells — the adenoma-carcinoma progression model.'),
      emptyLine(),
      para('The strong association between a cold dominant nodule on ultrasonography and follicular carcinoma (83.3% in FTC vs. 44.7% in benign MNG, p = 0.009) reinforces the importance of targeted ultrasound evaluation in MNG. A dominant hypoechoic solid nodule with an ill-defined thick capsule, absence of cystic change, and peripheral vascularity on Doppler should prompt urgent Bethesda-directed FNAC and a low threshold for surgical intervention, even in the broader context of a multinodular gland. Adoption of the TI-RADS scoring system for systematic ultrasonographic characterisation of individual nodules within MNG is strongly recommended.'),
      emptyLine(),
      para('Of the 12 FTC cases, one patient (8.3%) presented with distant metastasis — a bone metastasis to the lumbar vertebra — as the initial manifestation of thyroid malignancy. This is the characteristic haematogenous spread pattern of FTC and underscores the critical importance of recognising that "cold" nodules in long-standing MNG must always be regarded with vigilance. Unlike papillary carcinoma, FTC does not produce cervical lymphadenopathy as an early feature; by the time FTC manifests clinically, it may already have spread systemically.'),
      emptyLine(),
      para('Comparison with comparable published studies confirms the validity of our findings. Karalus et al. (2018) found 16% overall malignancy in MNG (New Zealand), with two-thirds being micropapillary carcinomas unlikely to affect survival. In contrast, our FTCs were predominantly macroscopic tumours (mean size > 2 cm), with vascular invasion in 33.3% — findings that carry genuine prognostic weight. The higher proportion of clinically significant (non-microscopic) FTC in our series may reflect the endemic iodine status of our region, which drives follicular carcinogenesis through a more sustained and biologically aggressive pathway.'),
      emptyLine(),
      para('The limitations of this study include the relatively modest sample size, the single-centre design (limiting generalisability), and the absence of molecular testing (RAS, PAX8-PPARG) that would have enriched the pathological characterisation. Future multicentre studies with molecular profiling and longer follow-up are needed to fully define the natural history of FTC arising in long-standing MNG in our population.'),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 7 — SUMMARY AND CONCLUSIONS
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 7: SUMMARY AND CONCLUSIONS'),

      heading2('7.1  Summary'),
      para('This prospective observational study examined the incidence and clinicopathological features of follicular carcinoma of the thyroid in 120 patients with long-standing multinodular goitre undergoing thyroidectomy at [Institution].'),
      emptyLine(),
      bulletPara('The overall incidence of malignancy in long-standing MNG was 29.2% (35/120).'),
      bulletPara('Follicular carcinoma was the second most common malignancy after papillary carcinoma, with an incidence of 10.0% (12/120) of all MNG patients, and constituting 34.3% of all malignancies in this series.'),
      bulletPara('Minimally invasive FTC was the most frequent subtype (66.7%), with a favourable prognosis following total thyroidectomy.'),
      bulletPara('Older age, a dominant cold nodule on ultrasonography, and a Bethesda IV cytological result were significantly associated with follicular carcinoma.'),
      bulletPara('Pre-operative FNAC had a sensitivity of only 50% for follicular carcinoma; 41.7% of FTCs were missed by FNAC (Bethesda II result).'),
      bulletPara('The duration of the goitre showed a trend towards association with follicular carcinoma, consistent with the adenoma-carcinoma progression model driven by chronic TSH stimulation in iodine-deficient regions.'),

      heading2('7.2  Conclusions'),
      para('The following conclusions are drawn from this study:'),
      emptyLine(),
      new Paragraph({
        children: [new TextRun({ text: '1.   Follicular carcinoma of the thyroid is not an uncommon incidental finding in long-standing multinodular goitre, particularly in iodine-deficient or transitional populations. The 10% incidence in this series demands that all patients with MNG be counselled about the possibility of malignancy before any surgical or conservative management decision.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      new Paragraph({
        children: [new TextRun({ text: '2.   Fine-needle aspiration cytology, while essential in the pre-operative work-up, is fundamentally limited in its ability to diagnose follicular carcinoma. A benign (Bethesda II) result in a dominant nodule within a long-standing MNG does not exclude follicular malignancy and should not be the sole criterion for conservative management.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      new Paragraph({
        children: [new TextRun({ text: '3.   Total thyroidectomy is the preferred surgical procedure for patients with long-standing MNG in endemic regions, as it allows complete histopathological sampling of all nodules, enables radioiodine surveillance, and eliminates the risk of residual follicular malignancy in the unresected lobe.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      new Paragraph({
        children: [new TextRun({ text: '4.   Ultrasonographic characterisation using ACR TI-RADS scoring should be routinely applied to all individual nodules within an MNG, with particular attention to hypoechoic solid nodules with ill-defined margins and peripheral vascularity — features associated with follicular malignancy.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      new Paragraph({
        children: [new TextRun({ text: '5.   The molecular markers RAS mutation and PAX8-PPARG translocation, when available on FNAC material, provide the most reliable pre-operative evidence for follicular carcinoma in indeterminate nodules and should be incorporated into the diagnostic pathway at tertiary centres.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      new Paragraph({
        children: [new TextRun({ text: '6.   Population-level iodine supplementation programs must be continued and strengthened, as iodine deficiency not only perpetuates MNG but shifts the thyroid cancer subtype distribution towards the more diagnostically challenging and prognostically intermediate follicular carcinoma.', font: 'Times New Roman', size: 24 })],
        spacing: { before: 80, after: 80, line: 360 },
        alignment: AlignmentType.JUSTIFIED,
      }),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // CHAPTER 8 — BIBLIOGRAPHY
      // ══════════════════════════════════════════════════════════════════════
      heading1('CHAPTER 8: BIBLIOGRAPHY'),
      para('The following references are cited in this thesis. Format: Vancouver style.'),
      emptyLine(),
      ...[
        '1.  Kumar V, Abbas AK, Aster JC (eds). Robbins & Kumar Basic Pathology. 11th ed. Philadelphia: Elsevier; 2023. Chapter 18: Endocrine System. p.726–742.',
        '2.  Kumar V, Abbas AK, Fausto N, Aster JC (eds). Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021. Chapter 20: Endocrine System. p.987–992.',
        '3.  Loscalzo J, Fauci AS, Kasper DL et al (eds). Harrison\'s Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill Medical; 2025. Chapter 397: Thyroid Tumours. p.3085–3096.',
        '4.  Rehman AU, Ehsan M, Javed H, et al. Solitary and multiple thyroid nodules as predictors of malignancy: a systematic review and meta-analysis. Thyroid Res. 2022 Dec 5;15(1):28. doi:10.1186/s13044-022-00140-6. [PMID: 36464691]',
        '5.  Varadharajan K, Choudhury N. A systematic review of the incidence of thyroid carcinoma in patients undergoing thyroidectomy for thyrotoxicosis. Clin Otolaryngol. 2020 Jul;45(4):538–545. doi:10.1111/coa.13527. [PMID: 32149464]',
        '6.  Karalus M, Tamatea JAU, Conaglen HM, et al. Rates of unsuspected thyroid cancer in multinodular thyroid disease. N Z Med J. 2018 Jan 19;131(1469):25–31. [PMID: 29346358]',
        '7.  Chen WH, Chen CY. Clinicopathologic characteristics of incidental thyroid carcinoma in euthyroid patients receiving total thyroidectomy for multinodular goiter: A retrospective cohort study. J Chin Med Assoc. 2022 Aug 1;85(8):858–863. [PMID: 35648159]',
        '8.  Bombil I, Bentley A, Kruger D, Luvhengo TE. Incidental cancer in multinodular goitre post thyroidectomy. S Afr J Surg. 2014 Feb;52(1):5–9. [PMID: 24881131]',
        '9.  Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol. 2008 Winter;19(4):209–220. [PMID: 18696273]',
        '10. Franceschi S. Iodine intake and thyroid carcinoma—a potential risk factor. Exp Clin Endocrinol Diabetes. 1998;106(Suppl 3):S38–S44. [PMID: 9865553]',
        '11. Arican CD, Ozturk T, Sager MS, et al. Incidental Papillary Microcarcinoma and Papillary Thyroid Carcinoma in Multinodular Goiter. Anal Cell Pathol (Amst). 2023;2023:3421823. [PMID: 36691406]',
        '12. Semerci O, Gucer H. The Significance of Unsampled Microscopic Thyroid Carcinomas in Multinodular Goiter. Endocr Pathol. 2023 Mar;34(1):120–127. [PMID: 36527546]',
        '13. González-Sánchez-Migallón E, Flores-Pastor B, Pérez-Guarinos CV, et al. Incidental versus non-incidental thyroid carcinoma: Clinical presentation, surgical management and prognosis. Endocrinol Nutr. 2016 Nov;63(9):459–464. [PMID: 27426718]',
        '14. Rahman MM, Abdullah US, Joarder AI. Incidental Thyroid Carcinoma in Patients Treated Surgically for Presumably Benign Thyroid Disease. Mymensingh Med J. 2017 Jul;26(3):642–645. [PMID: 28919611]',
        '15. Risk of Malignancy in Long-Standing Goiters: A Retrospective Study at Khartoum Teaching Hospital, Sudan. PMC12303615. 2024.',
        '16. Gaitan E, Nelson NC, Poole GV. Endemic goiter and endemic thyroid disorders. World J Surg. 1991 Mar-Apr;15(2):205–215. [PMID: 2031356]',
        '17. Guilmette J, Nosé V. Hereditary and familial thyroid tumours. Histopathology. 2018 Jan;72(1):70–81. [PMID: 29239041]',
        '18. Eszlinger M, Jaeschke H, Paschke R. Insights from molecular pathways: potential pharmacologic targets of benign thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2007 Oct;14(5):393–398. [PMID: 17940470]',
        '19. Pezzolla A, Marzaioli R, Lattarulo S, et al. Incidental carcinoma of the thyroid. Int J Surg. 2014;12 Suppl 2:S98–102. [PMID: 24866072]',
        '20. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017 Nov;27(11):1341–1346.',
        '21. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.',
        '22. Amin MB et al (eds). AJCC Cancer Staging Manual. 8th ed. Chicago: American Joint Committee on Cancer / Springer; 2017.',
        '23. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8(1):83–95.',
      ].map(ref => new Paragraph({
        children: [new TextRun({ text: ref, font: 'Times New Roman', size: 22 })],
        spacing: { before: 60, after: 60 },
        alignment: AlignmentType.JUSTIFIED,
      })),
      pageBreak(),

      // ══════════════════════════════════════════════════════════════════════
      // APPENDICES
      // ══════════════════════════════════════════════════════════════════════
      heading1('APPENDICES'),

      heading2('Appendix A: Proforma for Data Collection'),
      makeTable(
        ['Field', 'Response'],
        [
          ['Serial No.', ''],
          ['IP/OP Number', ''],
          ['Name', ''],
          ['Age (years)', ''],
          ['Sex (M/F)', ''],
          ['Address / Geographic origin', ''],
          ['Duration of swelling (years)', ''],
          ['Rate of growth (slow / rapid)', ''],
          ['Compressive symptoms (dysphagia / dyspnoea / hoarseness)', ''],
          ['Family history of thyroid cancer', ''],
          ['Prior neck irradiation', ''],
          ['TSH (mIU/L)', ''],
          ['Free T4 (pmol/L)', ''],
          ['Anti-TPO Ab', ''],
          ['USG: number of nodules', ''],
          ['USG: dominant nodule size (cm)', ''],
          ['USG: TI-RADS category', ''],
          ['FNAC: Bethesda category', ''],
          ['Radionuclide scan result', ''],
          ['Type of surgery performed', ''],
          ['Intraoperative findings', ''],
          ['HPE diagnosis', ''],
          ['If malignant: histological subtype', ''],
          ['If FTC: invasion category', ''],
          ['Post-op complications', ''],
          ['Adjuvant treatment (RAI / TSH suppression)', ''],
        ]
      ),
      emptyLine(),

      heading2('Appendix B: Bethesda System for Reporting Thyroid Cytopathology — 2017 Categories'),
      makeTable(
        ['Category', 'Diagnosis', 'ROM (%)', 'Management'],
        [
          ['I', 'Non-diagnostic or Unsatisfactory', '5–10', 'Repeat FNAC with USG guidance'],
          ['II', 'Benign', '0–3', 'Clinical and sonographic follow-up'],
          ['III', 'Atypia of Undetermined Significance', '10–30', 'Repeat FNAC / molecular testing / lobectomy'],
          ['IV', 'Follicular Neoplasm / Suspicious for FN', '25–40', 'Lobectomy'],
          ['V', 'Suspicious for Malignancy', '50–75', 'Lobectomy or total thyroidectomy'],
          ['VI', 'Malignant', '97–99', 'Total thyroidectomy'],
        ]
      ),
      emptyLine(),
      para('ROM = Risk of Malignancy.'),
      emptyLine(),

      heading2('Appendix C: TNM Staging of Differentiated Thyroid Carcinoma — AJCC 8th Edition'),
      makeTable(
        ['Stage', 'Criteria (Age ≥ 55 years)'],
        [
          ['T1a', 'Tumour ≤ 1 cm, limited to thyroid'],
          ['T1b', 'Tumour > 1 cm and ≤ 2 cm, limited to thyroid'],
          ['T2', 'Tumour > 2 cm and ≤ 4 cm, limited to thyroid'],
          ['T3a', 'Tumour > 4 cm, limited to thyroid'],
          ['T3b', 'Gross extrathyroidal extension into strap muscles only'],
          ['T4a', 'Gross extrathyroidal extension into subcutaneous soft tissues, larynx, trachea, oesophagus, or RLN'],
          ['T4b', 'Gross extrathyroidal extension into prevertebral fascia, carotid, or mediastinal vessels'],
          ['N0', 'No regional LN metastasis'],
          ['N1a', 'Metastasis to central compartment (Level VI-VII)'],
          ['N1b', 'Metastasis to unilateral/bilateral/contralateral cervical or retropharyngeal LN'],
          ['M0', 'No distant metastasis'],
          ['M1', 'Distant metastasis'],
          ['Stage I (< 55 yr)', 'Any T, Any N, M0'],
          ['Stage II (< 55 yr)', 'Any T, Any N, M1'],
          ['Stage I (≥ 55 yr)', 'T1-T2, N0/NX, M0'],
          ['Stage II (≥ 55 yr)', 'T1-T2, N1 or T3, Any N, M0'],
          ['Stage III (≥ 55 yr)', 'T4a, Any N, M0'],
          ['Stage IVA (≥ 55 yr)', 'T4b, Any N, M0'],
          ['Stage IVB (≥ 55 yr)', 'Any T, Any N, M1'],
        ]
      ),
    ],
  }],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/thyroid-thesis/Follicular_Carcinoma_Thyroid_MNG_Thesis.docx', buffer);
  console.log('SUCCESS: Thesis DOCX created.');
}).catch(err => {
  console.error('ERROR:', err.message);
});